Practitioner review: Psychopharmacology in children and adolescents with mental retardation

Journal of Child Psychology and Psychiatry and Allied Disciplines

Volumn 47, Issue 9, 2006, Pages 871-882

  Handen, Benjamin L ^a,c   Gilchrist, Richard ^b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b AKRON CHILDREN'S HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Adolescents; Children; Mental retardation; Psychopharmcology

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; CITALOPRAM; CLOZAPINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; LITHIUM CARBONATE; METADATE SR; METHYLPHENIDATE; MIRTAZAPINE; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OXCARBAZEPINE; PAROXETINE; PEMOLINE; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERAPHEM; SERTRALINE; UNINDEXED DRUG; VALPROATE SEMISODIUM; VALPROIC ACID; VENLAFAXINE; ZIPRASIDONE;

ABDOMINAL PAIN; ACNE; ADOLESCENT; AGGRESSION; AGITATION; AGRANULOCYTOSIS; AKATHISIA; ALOPECIA; ANOREXIA; ATAXIA; ATTENTION DEFICIT DISORDER; AUTOMUTILATION; BIPOLAR DISORDER; BLURRED VISION; BODY WEIGHT DISORDER; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CHILD; CLINICAL TRIAL; COGNITIVE DEFECT; COMA; CONSTIPATION; DELIRIUM; DEPRESSION; DIABETES INSIPIDUS; DIARRHEA; DIZZINESS; DRUG ERUPTION; DRUG FATALITY; DRUG MONITORING; DRUG SAFETY; DRUG USE; DYSKINESIA; DYSPEPSIA; DYSTONIA; ELECTROLYTE DISTURBANCE; FATIGUE; GALACTORRHEA; GASTROINTESTINAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; GROWTH RETARDATION; GYNECOMASTIA; HEADACHE; HEART ARRHYTHMIA; HEART DISEASE; HEMORRHAGIC PANCREATITIS; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERSALIVATION; HYPERTENSION; HYPOMANIA; HYPOTHYROIDISM; INFERTILITY; INSOMNIA; IRRITABILITY; LIVER FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MENSTRUAL IRREGULARITY; MENTAL DEFICIENCY; MOOD DISORDER; MOTOR DYSFUNCTION; MUSCLE WEAKNESS; NERVOUSNESS; NIGHTMARE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; OVARY CYST; OVARY POLYCYSTIC DISEASE; PARESTHESIA; PARKINSONISM; PNEUMONIA; POLYDIPSIA; POLYURIA; PSYCHOSIS; PSYCHOSOCIAL WITHDRAWAL; QT PROLONGATION; REVIEW; RHINITIS; SEDATION; SEIZURE; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; STEVENS JOHNSON SYNDROME; SYNCOPE; THROMBOCYTOPENIA; TIC; TOXIC EPIDERMAL NECROLYSIS; TREMOR; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; HUMANS; MENTAL RETARDATION; PSYCHOTROPIC DRUGS;

EID: 33747483306     PISSN: 00219630     EISSN: 14697610     Source Type: Journal    
DOI: 10.1111/j.1469-7610.2006.01588.x     Document Type: Review

References (91)

1. Aman, M.G., Arnold, L.E., & Armstrong, S.C. (1999). Review of serotonergic agents and perseverative behavior in patients with developmental disabilities. Mental Retardation and Developmental Disabilities, 5, 279-289.
2. Aman, M.G., Buican, B., & Arnold, L.E. (2003). Methylphenidate treatment in children with borderline IQ and mental retardation: Analysis of three aggregated studies. Journal of Child and Adolescent Psychopharmacology, 13, 29-40.
3. Aman, M.G., Collier-Crespin, A., & Lindsay, R.L. (2000). Pharmacotherapy of disorders in mental retardation. European Child and Adolescent Psychiatry, Supplement 1, 198-107.
4. Aman, M.G., Kern, R.A., McGhee, D.E., & Arnold, L.E. (1993). Fenfluramine and methylphenidate in children with mental retardation and ADHD: Clinical and side effects. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 851-859.
5. Aman, M.G., Kern, R.A., Osborne, P., Tumuluru, R., Rojahn, J., & del Medico, V. (1997). Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: Clinical effects. American Journal of Mental Retardation, 101, 521-534.
6. Aman, M.G., & Madrid, A. (1999). Atypical antipsychotics in persons with developmental disabilities. Mental Retardation and Developmental Disabilities, 5, 253-263.
7. Aman, M.G., Marks, R.E., Turbott, S.H., Wilsher, C.P., & Merry, S.N. (1991). Clinical effects of methylphenidate and thioridazine in intellectually subaverage children. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 246-256.
8. Aman, M.G., De Smedt, G., Derivan, A., Lyons, B., & Findling, R.L. (2002). Risperidone Disruptive Behavior Study Group. Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. American Journal of Psychiatry, 159, 1337-1346.
9. Antochi, R., Stavrakaki, C., & Emery, P.C. (2003). Psychopharmacological treatments in persons with dual diagnosis of psychiatric disorders and developmental disabilities. Postgraduate Medicine Journal, 9, 139-146.
10. Branford, D., Bhaumik, S., & Naik, B. (1998). Selective serotonin re-uptake inhibitors for the treatment of perseverative and maladaptive behaviours of people with intellectual disability. Journal of Intellectual Disability Research, 42, 301-306.
11. Centorrino, F., Albert, M.J., Berry, J.M., Kelleher, J.P., Fellman, V., Line, G., Koukopoulos, A.E., Kidwell, J.E., Fogarty, K.V., & Baldessarini, R.J. (2003). Oxcarbazepine: Clinical experience with hospitalized psychiatric patients. Bipolar Disorder, 5, 370-374.
12. Cohen, S., Fitzgerald, B., Okos, A., Khan, S., & Khan, A. (2003). Weight, lipids, glucose, and behavioral measures with ziprasidone treatment in a population with mental retardation. Journal of Clinical Psychiatry, 64, 60-62.
13. Conners, C.K., Casat, C.D., Gualtieri, C.T., Weller, E., Reader, M., Reiss, A., Weller, R.A., Khayrallah, M., & Ascher, J. (1996). Bupropion hydrochloride in attention deficit disorder with hyperactivity. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1314-1321.
14. Curtis, J.L. (1997). Psychotropic medication use in people with developmental disabilities. Maryland Medical Journal, 46, 481-485.
15. Davanzo, P.A., Belin, T.R., Widawski, M.H., & King, B.H. (1998). Paroxetine treatment of aggression and self-injury in persons with mental retardation. American Journal of Mental Retardation, 102, 427-437.
16. DeLong, G.R., Ritch, C.R., & Burch, S. (2002). Fluoxetine response in children with autistic spectrum disorders: Correlation with familial major affective disorder and intellectual achievement. Developmental Medicine and Child Neurology, 44, 652-659.
17. DesNoyers Hurley, A., Reiss, S., Aman, M.G., Salvador-Carulla, L., Demb, H., Loschen, E., & Einfield, S. (1998). Instruments for assessing effects in psychotropic medication. In S. Reiss & M.G. Aman (Eds.), The international consensus handbook: Psychotropic medications and developmental disabilities (pp. 85-94). Columbus, OH: Nisonger Center.
18. Eiland, L.S, & Guest, A.L. (2004). Atomoxetine treatment of attention-deficit/hyperactivity disorder. Annals of Pharmacotherapy, 38, 86-90.
19. Emerson, E. (2003). Prevalence of psychiatric disorders in children and adolescents with and without intellectual disability. Journal of Intellectual Disability Research, 47, 51-58.
20. Fankhauser, M., Marumanchi, V., German, M., Yates, A., & Karumanchi, S. (1992). A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. Journal of Clinical Psychiatry, 53, 77-82.
21. FDA Public Health Advisory, October 15, 2004.
22. FDA Talk Paper (August 5, 2005). 1 PV 3758 AMP STRATTERA® (atomoxetine HCl) DESCRIPTION STRATTERA® (atomoxetine HCl) is a selective norepinephrine reuptake inhibitor. Atomoxetine HCl is... http://www.fda.gov/medwatch/SAFETY/2005/MAY_PI/Strattera_PI.pdf.
23. Fenichel, G.M. (1997). Clinical pediatric neurology: A signs and symptoms approach. Philadelphia, PA: W.B. Saunders Company.
24. Friedlander, R., Lazar, S., & Klancnik, J. (2001). Atypical antipsychotic use in treating adolescents and young adults with developmental disabilities. Canadian Journal of Psychiatry, 46, 741-745.
25. Fukuda, T., Sugie, H., Ito, M., & Sugie, Y. (2001). Clinical evaluation of treatment with fluvoxamine, a selective serotonin reuptake inhibitor in children with autistic disorder. No to Hattatsu [Brain and Development], 33, 314-318.
26. Gehlert, D.R., Gackenheimer, S.L., & Rovertson, D.W. (1993). Localization of rat brain binding sites for [3H] atomoxetine, an enantiomerically pure ligand for norephinephrine reuptake sites. Neuroscience Letter, 157, 203-206.
27. Green, W.H. (2001). Child and adolescent clinical psychopharmacology. Philadelphia, PA: Lippincott Williams & Wilkins.
28. Greenhill, L.L., Swanson, J.M., Vitiello, B., Davies, M., Clevenger, W., Wu, M., Arnold, L.E., Abikoff, H.B., Bukstein, O.G., Conners, C.K., Elliott, G.R., Hechtman, L., Hinshaw, S.P., Hoza, B., Jensen, P.S., Kraemer, H.C., March, J.S., Newcorn, J.H., Severe, J.B., Wells, K., & Wigal, T. (2001). Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 180-187.
29. Handen, B.L., Breaux, A.M., Gosling, A., Ploof, D.L., & Feldman, H. (1990). Efficacy of Ritalin among mentally retarded children with ADHD. Pediatrics, 86, 922-930.
30. Handen, B.L., Breaux, A.M., Janosky, J., McAuliffe, S., Feldman, H., & Gosling, A. (1992). Effects and noneffects of methylphenidate in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 455-461.
31. Handen, B.L., Feldman, H., Gosling, A., Breaux, A.M., & McAuliffe, S. (1991). Adverse side effects of Ritalin among mentally retarded children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 241-245.
32. Handen, B.L., & Gilchrist, R.H. (2006). Mental retardation. In E. Mash & R.A. Barkley (Eds.), Treatment of childhood disorders (3rd edn), pp. 411-454. New York: Guilford Press.
33. Handen, B.L., Janosky, J., McAuliffe, S., Breaux, A.M., & Feldman, H. (1994). Prediction of response to methylphenidate among children with ADHD and mental retardation. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 1185-1193.
34. Handen, B.L., McAuliffe, S., & Caro-Martinez, L. (1996). Learning effects of methylphenidate in children with mental retardation. Journal of Developmental and Physical Disabilities, 8, 335-346.
35. Handen, B.L., McAuliffe, S., Janosky, J., Breaux, A. M., & Feldman, H. (1995). Methylphenidate in children with mental retardation and ADHD: Effects on independent play and academic functioning. Journal of Developmental and Physical Disabilities, 7, 91-103.
36. Handen, B.L., Sahl, R., & Hardan, A. (in press). Open label, prospective trial of olanzapine in adolescents with subaverage intelligence and disruptive behavioral disorders. Journal of the American Academy of Child and Adolescent Psychiatry.
37. Hardan, A., Roger, J., & Handen, B. (in press). Quetiapine open-label trial in children and adolescents with developmental disorder. Journal of Pediatric Neurology.
38. Hellings, J.A. (1999). Psychopharmacology of mood disorders in persons with mental retardation and autism. Mental Retardation and Developmental Disabilities Research Reviews, 5, 270-278.
39. Hellings, J.A., Cardona, A., Zarcone J.R., Ward, S.M., & Schroeder, S.R. (2004). Long-term safety and adverse events of risperidone in children, adolescents, and adults with MR/DD. Abstract of poster presented at 44th Annual Meeting of the NCDEU.
40. Hellings, J.A., Kelley, L.A., Gabrielli, W.F., Kilgore, E., & Shah, P. (1996). Sertraline response in adults with mental retardation and autistic disorder. Journal of Clinical Psychiatry, 57, 333-336.
41. Hellings, J.A., Zarcone, J.R., Crandall, K., Wallace, D., & Schroeder, S.R. (2001). Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. Journal of Child and Adolescent Psychopharmacology, 11, 229-238.
42. Hellings, J.A., Zarcone, J.R., Reese, R.M., Valdovinos, M.G., Marquis, J.G., Fleming, K.K., & Schroeder, S.R. (in press). A crossover study of risperidone in children, adolescents and adults with mental retardation. Journal of Autism Developmental Disorders.
43. Hyman, S.E., Arana, G.W., & Rosenbaum, J.F. (1995). Handbook of psychiatric drug therapy. Boston, MA: Little, Brown and Company.
44. Janowsky, D.S., Barnhill, L.J., & Davis, J.M. (2003). Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: A retrospective, open-label, naturalistic trial. Journal of Clinical Psychiatry, 64, 1258-1265.
45. Jaselskis, C.A., Cook, E.H., & Fletcher, K.E. (1992). Clonidine treatment of hyperactive and impulsive children with autistic disorder. Journal of Clinical Psychopharmacology, 12, 322-237.
46. Jorde, L.B., Carey, J.C., & White, R.L. (1995). Medical genetics. St. Louis, MO: Mosby.
47. Kaplan, H.I., & Sadock, B.J. (1993). Psychiatric drug treatment. Baltimore, MD: Williams & Wilkins.
48. Keck, P.E. Jr (2003). Long-term therapy of bipolar illness. Journal of Family Practice, Supplement, S18-21.
49. Ketter, T.A., Wang, P.W., Becker, O. V., Nowakowska, C., & Yang, Y.S. (2003). The diverse roles of anticonvulsants in bipolar disorders. Annals of Clinical Psychiatry, 15, 95-108.
50. Kowatch, R.A., & Bucci, J.P. (1998). Mood stabilizers and anticonvulsants. Pediatric Clinics of North America, 45, 1173-1186.
51. Krishnamoorthy, J., & King, B.H. (1998). Open-label olanzapine treatment in five preadolescent children. Journal of Child and Adolescent Psychopharmacology, 8, 7-13.
52. La Malfa, G., Bertelli, M., & Conte, M. (2001). Fluvoxamine and aggression in mental retardation. Psychiatric Services, 52, 1105.
53. Luiselli, J.K., Blew, P., & Thibadeau, S. (2001). Therapeutic effects and long-term efficacy of antidepressant medication for persons with developmental disabilities. Behavioral assessment in two cases of treatment-resistant aggression and self-injury. Behavior Modification, 25, 62-78.
54. Madrid, A.L., State, M.W., & King, B.H. (2000). Pharmacologic management of psychiatric and behavioral symptoms in mental retardation. Child and Adolescent Psychiatry Clinics of North America, 9, 225-243.
55. Marriage, K. (2002). Schizophrenia and related psychoses. In S. Kutcher (Ed.), Practical child and adolescent psychopharmacology (pp. 134-158). New York: Cambridge University Press.
56. Martin, A., Koenig, K., Scahill, L., & Bregman, J. (1999). Open-label quetiapine in the treatment of children and adolescents with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 9, 99-107.
57. Masi, G., Marcheschi, M., & Pfanner, P. (1997). Paroxetine in depressed adolescents with intellectual disability: An open label study. Journal of Intellectual Disability Research, 41, 268-272.
58. McCracken, J.T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M.G., Arnold, L.E., Lindsay, R., Nash, P., Hollway, J., McDougle, C.J., Posey, D., Swiezy, N., Kohn, A., Scahill, L., Martin, A., Koenig, K., Volkmar, F., Carroll, D., Lancor, A., Tierney, E., Ghuman, J., Gonzalez, N.M., Grados, M., Vitiello, B., Ritz, L., Davies, M., Robinson, J., & McMahon, D. (2002). Research Units on Pediatric Psychopharmacology Autism Network. Risperidone in children with autism and serious behavioral problems. New England Journal of Medicine, 347, 314-321.
59. McDermott, S., Moran, R., Platt, T., Wood, H., Isaac, T., & Dasari, S. (2005). Prevalence of epilepsy in adults with mental retardation and related disabilities in primary care. American Journal on Mental Retardation, 110, 36-47.
60. McDonough, M., Hillery, J., & Kennedy, N. (2000). Olanzapine for chronic, stereotypic self-injurious behaviour: A pilot study in seven adults with intellectual disability. Journal of Intellectual Disability Research, 44, 677-684.
61. McDougle, C.J. (1998). Efficacy of fluvoxamine in children with autistic disorder. Unpublished manuscript.
62. McDougle, C.J., Brodkin, E.S., Naylor, S.T., Carlson, D.C., Cohen, D.J., & Price, L.H. (1998). Sertraline in adults with pervasive developmental disorders: A prospective open-label investigation. Journal of Clinical Psychopharmacology, 18, 62-66.
63. McDougle, C.J., Kem, D.L., & Posey, D.J. (2002). Case series: Use of ziprasidone for maladaptive symptoms in youths with autism. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 921-927.
64. McDougle, C.J., Naylor, T., Cohen, D., Volkmar, F.R., Heninger, G.R., & Price, L.H. (1996). A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Archives of General Psychiatry, 53, 1001-1008.
65. Pacher, P., & Kecskemeti, V. (2004). Cardiovascular side effects of new antidepressants and antipsychotics: New drugs, old concerns? Current Pharmaceutical Design, 10, 2463-2475.
66. Pearson, D.A., Santos, C., Roache, J., Casat, C., Loveland, K.A., Lachar, D., Lane, D.M., Faria, L., & Cleveland, L. (2003). Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 209-216.
67. Posey, D.I., Litwiller, M., Koburn, A., & McDougle, C.J. (1999). Paroxetine in autism. Letter] Journal of the American Academy of Child and Adolescent Psychiatry, 38, 111-112.
68. Physician's desk reference. (2004). Oradell, NJ: Medical Economics Co.
69. Posey, D.J., Puntney, J.I., Sasher, T.M., Kem, D.L., Kohn, A., & McDougle, C.J. (2004). Guanfacine treatment of hyperactivity and inattention in pervasive developmental disorders: A retrospective analysis of 80 cases. Journal of Child and Adolescent Psychopharmacology, 14, 233-242.
70. Reiss, A., Levitan, G.W., & Szyszko, K. (1982). Emotional disturbance and mental retardation: Diagnostic overshadowing. American Journal of Mental Deficiency, 86, 567-574.
71. Ruedrich, S., Swalesm, T.P., Fossaceca, C., Toliver, J., & Rutkowski, A. (1999). Effect of divalproex sodium on aggression and self-injurious behaviour in adults with intellectual disability: A retrospective review. Journal of Intellectual Disability Research, 43, 105-111.
72. Sallee, F.R., DeVane, C.L., & Ferrell, R.E. (2000). Fluoxetine-related death in a child with cytochrome P-450 2D6 genetic deficiency. Journal of Child and Adolescent Psychopharmacology, 10, 27-34.
73. Santosh, P.J., & Baird, G. (1999). Psychopharmacotherapy in children and adults with intellectual disability. Lancet, 354, 233-242.
74. Shaffer, D., Fisher, P., Dulcan, M., Davies, M., Piacentini, J., Schwab-Stone, M.E., Lahey, B.B., Bourdon, K., Jensen, P.S., Bird, H.R., Canino, G., & Regier, D. (1996). The NIMH Diagnostic Interview Schedule for Children version 2.3 (DISC-2.3): Description, acceptability, prevalence rates and performance in the MECA study. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 865-877.
75. Singh, N., Ellis, C., & Wechsler, H. (1997). Psychopharmacoepidemiology of mental retardation: 1966 to 1995. Journal of Child and Adolescent Psychopharmacology, 7, 255-266.
76. Snead, R.W., Boon, F., & Presberg, J. (1994). Paroxetine for self-injurious behavior. Journal of the American Academy of Child and Adolescent Psychiatry, 33, 909-910.
77. Sovner, R., Pary, R.J., Dosen, A., Gedye, A., Barrera, F., Cantwell, D.P., & Huessy, H. (1998). Antidepressant drugs. In S. Reiss & M.G. Aman (Eds.), The international consensus handbook: Psychotropic medications and developmental disabilities (pp. 179-200). Columbus, OH: Nisonger Center.
78. Spencer, T., Heiligenstein, J., Biederman, J., Faries, D.E., Kratochvil, C.J., Conners, C.K., & Potter, W.Z. (2002). Results from 2 proof-of-concept, placebocontrolled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. Journal of Clinical Psychiatry, 63, 1140-1147.
79. Staller, J.A. (2003). Aripiprazole in an adult with Asperger disorder. Annals of Pharmacotherapy, 37, 1628-1631.
80. Steingard, R.J., Zimnitzky, B., DeMaso, D.R., Bauman, M.L., & Bucci, J.P. (1997). Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. Journal of Child and Adolescent Psychopharmacology, 7, 9-15.
81. Stigler, K.A., Posey, D.J., & McDougle, C.J. (2004). Aripiprazole for maladaptive behavior in pervasive developmental disorders. Journal of Child and Adolescent Psychopharmacology, 14, 455-63.
82. Stolker, J.J., Koedoot, P.J., Heerdink, E.R., Leufkens, H.G., & Nolen, W.A. (2002). Psychotropic drug use in intellectually disabled group-home residents with behavioural problems. Pharmacopsychiatry, 35, 19-23.
83. Stromme, P., & Diseth, T.H. (2000). Prevalence of psychiatric diagnoses in children with mental retardation: Data from a population-based study. Developmental Medicine and Child Neurology, 42, 266-270.
84. Troisi, A. (1997). Fluoxetine and aggression. Neuropsychopharmacology, 16, 373-374.
85. Turgay, A., Binder, C., Snyder, R., & Fisman, S. (2002). Long-term safety and efficacy of risperidone for the treatment of disruptive behavior disorders in children with subaverage IQs. Pediatrics, 110, e34.
86. Van Bellinghen, M., & De Troch, C. (2001). Risperidone in the treatment of behavioral disturbances in children and adolescents with borderline intellectual functioning: A double-blind, placebo-controlled pilot trial. Journal of Child and Adolescent Psychopharmacology, 11, 5-13.
87. Vanstraelen, M., & Tyrer, S.P. (1999). Rapid cycling bipolar affective disorder in people with intellectual disability: A systematic review. Journal of Intellectual Disability Research, 43, 349-359.
88. Verhoeven, W.M., Veendrik-Meekes, M.J., Jacobs, G.A., den Berg, Y.W., & Tuinier, S. (2001). Citalopram in mentally retarded patients with depression: A longterm clinical investigation. European Psychiatry, 16, 104-108.
89. Williams, H., Clarke, R., Bouras, N., Martin, J., & Holt, G. (2000). Use of the atypical antipsychotics Olanzapine and Risperidone in adults with intellectual disability. Journal of Intellectual Disability Research, 44, 164-169.
90. Wong, D.T., Threlkeld, P.G., Best, K.L., & Bymaster, F.P. (1982). A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. Journal of Pharmacology and Experimental Therapy, 222, 61-65.
91. Zarcone, J.R., Lindauer, S.E., Morse, P.S., Crosland, K.A., Valdovinos, M.G., McKerchar, T.L., Matthew, R.R., Hellings, J.A., & Schroeder, S.R. (2004). Effects of risperidone on destructive behavior of persons with developmental disabilities: III. Functional analysis. American Journal of Mental Retardation, 109, 310-321.